About Us – Esolate

Our Team

The Esolate team is a list of proven professionals who provide the necessary expertise, experience, passion and vision for success.

	Hardin Jackson, Chief Executive Officer Hardin brings years of experience in start-ups and new venture development across industrial, manufacturing, technology and cannabis market verticals. In addition to significant experience in setting business strategy for all market verticals, Hardin manages the Canadian API and formulations operations spearheading production and process design teams across the group’s cannabis, wellness, psychedelic, and pharmaceutical initiatives. Hardin bridges the links between strategy, business development, client relations, and scientific innovations.
	Mark Goliger, Board Member Mark leads the group’s commercialization and licensing initiatives and consummates relationships with our partners across our businesses. Mark has been a key figure in the cannabis market vertical. In his most recent position as CEO of Meta Growth, Mark was instrumental in starting businesses in medicinal cannabis distribution in Canada. Upon legalization, Meta grew into recreational retail cannabis, becoming an industry leader with a footprint of 35 outlets across five provinces. Through his direction as CEO, revenues grew from $1.2m to greater than $55m. As a public traded company, Meta grew to over 400 employees and successfully merged to become the largest cannabis retailing group in Canada.
	Julian Bryson, Non-Executive Director Julian is responsible for the group’s IP development, licensing strategy and EU and UK business development as well ensuring the transatlantic operations of the Group run smoothly on the commercial as well as the scientific teams level. Julian previously acquired the worldwide rights, and subsequently patented, a novel medical devices sterilization technology. As a result, Julian founded medical systems development specialist Sterilox Technologies, which listed on the London Stock Exchange as life sciences specialist Puricore plc, valued at £100m. The business was subsequently acquired by Cantel Medical Corp (NYSE:CMD).
	Jinhee Oh, MSc. Chief Science Officer Jinhee overseas the Esolate formulations development, as well as leading bespoke client product design for Esolate licensees across formulation portfolio. Jinhee is a leading expert in the proprietary technology underpinning the Esolate offering and IP. She is an expert in the field of applied chemical engineering and cannabinoid research, and is responsible for Esolate’s chemical and process engineering design. Previously instrumental in the design, development and production of cannabis extraction facilities, laboratories, post processing plant technologies and CPG formulations design. Jinhee was formerly research division lead at LG Chem and is an inventor on LG patents. She acted as a Commissioned Research Scientist at Korea Institute of Science and Technology.
	Dr. Devin Machin PhD., Head Biochemist Devin is responsible for the development of Esolate’s cannabinoid formulations portfolio at the pure chemistry level, leading the Company’s proprietary formulation research and development throughout the biochemical research phase, as well as designing and running technical research for in-house and client applied product solutions Devin is an alumni of the renowned research team at the Department of Chemical and Biochemical Engineering at University of Western Ontario, and an expert in chemical synthesis of cannabinoids and derivative formulations.
	Darrell Lowes, R&D Lead - Psychedelics Division As an established CPG entrepreneur Darrell plays a key role in coordinating product development projects. Additionally, Darrell is our team lead for research and development for the Psychedelics Division. Areas of focus include: Psilocybin Pharmacology, Effects, and Safety. Clinical Trial Findings of Psilocybin Treatment for Depression and other Psychiatric Indications. History, Psychological Mechanisms, and Microsdosing/ Psilocybin Assisted Therapies. And the Neurobiological Effects of Psilocybin.
	Michael Saliken, Legal Counsel - BLG Michael is a partner at Borden Ladner Gervais LLP, where he focuses on commercial transactions and corporate governance for issuers, investment banks and private equity firms. Michael sits on the steering committee of BLG's Psychedelics and Cannabis Focus Group and is a board member and advisor to various businesses and NPOs.